Bevacizumab compared with steroids for brain damage caused by radiation
Original title: Bevacizumab Versus Corticosteroids as First-line Treatment in Patients With Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large late stage trial, so the treatment is being tested in many people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests whether a drug called bevacizumab works better than steroids as the first treatment for brain swelling and damage caused by radiation.
Who this trial is for. This trial is for people who had radiation for a high grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary or for cancer that spread to the brain, and who now have symptoms from radiation damage in the brain. It compares bevacizumab, given as the first treatment, with dexamethasone, the steroid usually used first.
Where it stands. The trial is comparing how well each treatment works for these symptoms. The best first treatment is not known yet. This trial has not reported results.
What this means, and what it doesn't
What it could mean: Steroids can cause problems of their own and do not always control the symptoms. This trial is looking for a first treatment that works better and is easier on the body. Someone who fits this picture could ask their care team whether this trial is worth looking into.
What it doesn't mean: This does not mean bevacizumab is a proven first treatment for this problem. A trial is a test. It is run because the answer is not known. Joining a trial is not a guarantee that you will be helped, and it is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, July 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.